FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2901938171> ?p ?o ?g. }

• W2901938171 endingPage "140" @default.
• W2901938171 startingPage "140" @default.
• W2901938171 abstract "Abstract Introduction Lymphoma patients are at increased risk of thromboembolic events (TE), however, thromboprophylaxis in these patients is largely under utilized. Actual guidelines recommend different models for thromboembolic risk estimation in cancer patients. Proposed models are of limited use in lymphoma patients as their development is not based on specific characteristics for this patient population. Previously, we developed and internally validated a simple model, based on individual clinical and laboratory patient characteristics that would classify lymphoma patients at risk for a TE. The variables independently associated with the risk for thromboembolism were: previous venous and/or arterial events, mediastinal involvement, BMI>30 kg/m2, reduced mobility, extranodal localization, development of neutropenia and hemoglobin level < 100g/L. For patients classified at risk in derivation cohort (n=1236), the model revealed positive predictive value of 25.1%, negative predictive value of 98.5%, sensitivity of 75.4%, and specificity of 87.5%. The diagnostic performance measures retained similar values in the internal validation cohort (n=584). The aim of this study was to perform external validation of the previously developed thrombosis lymphoma (Throly) score. Methods The study population included patients with a confirmed diagnosis of non-Hodgkin lymphoma (NHL), Hodgkin lymphoma (HL), and chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL) from 8 lymphoma centers from USA, France, Spain, Croatia, Austria, Switzerland, Macedonia, and Jordan. During 2015 to 2016, data were prospectively collected for venous TE events from time of diagnosis to 3 months after the last cycle of therapy for newly diagnosed and relapsed patients who had completed a minimum of one chemotherapy cycle. The score development and validation were done according to TRIPOD suggested guidelines. Sensitivity analyses were carried out to test the model robustness to possible different settings, according to in/out patient settings and according to different countries included. Results External validation cohort included 1723 patients, similar to the developed group and consisted of 467 indolent NHL, 647 aggressive NHL, 235 CLL/SLL and 366 HL patients, out of which 121 (7%) patients developed venous thromboembolic events. For patients classified at risk in external validation cohort, the model resulted in positive and negative predictive values of 17% and 93%, respectively. Based on new available information from this large prospective cohort study this model was revised to include the following variables: diagnosis/clinical stage, previous VTE, reduced mobility, hemoglobin level < 100g/L and presence of vascular devices. In the new score we divided patients in two groups: low risk patients, score value ≤ 2; and high risk patients, score value > 2. For patients classified at risk by the revised model, the model produced positive predictive value of 22%, negative predictive value of 96%, sensitivity of 51%, and specificity of 72%. In sensitivity analysis, the final model proved its robustness in different settings of major importance for lymphoma patients. The final model presented good discrimination and calibration performance. Concordance C statistics was 0.794 (95% CI 0.750-0.837). Conclusions Revised Thrombosis Lymphoma - ThroLy score is more specific for lymphoma patients than any other available score targeting thrombosis risk in solid cancer patients. We included biological characteristic of lymphoma, indolent vs aggressive, as well as data about dissemination of disease, localized vs advanced stage, reflecting specificity of lymphomas comparing to other types of cancer. Also, we pointed out significance of central vascular devices as risk factor having considered the role of vascular damage during insertion as a potential trigger for activation of the clotting cascade. This score is user friendly for daily clinical practice and provides a very good predictive power to identify patients who are candidates for pharmacological thromboprophylaxis. Disclosures Cheson: AbbVie, Roche/Genentech, Pharmacyclics, Acerta, TG Therapeutics: Consultancy. Ghielmini:Roche: Consultancy, Honoraria, Research Funding, Speakers Bureau. Jaeger:Gilead: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Celgene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees, Research Funding; AOP Orphan: Membership on an entity's Board of Directors or advisory committees; Roche: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Janssen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; MSD: Research Funding; Bioverativ: Membership on an entity's Board of Directors or advisory committees; AbbVie: Consultancy, Honoraria; Mundipharma: Membership on an entity's Board of Directors or advisory committees; Takeda-Millenium: Membership on an entity's Board of Directors or advisory committees; Takeda-Millenium: Membership on an entity's Board of Directors or advisory committees; Amgen: Membership on an entity's Board of Directors or advisory committees; GSK: Membership on an entity's Board of Directors or advisory committees; Infinity: Membership on an entity's Board of Directors or advisory committees." @default.
• W2901938171 created "2018-11-29" @default.
• W2901938171 creator A5003886811 @default.
• W2901938171 creator A5004490449 @default.
• W2901938171 creator A5007859032 @default.
• W2901938171 creator A5024688180 @default.
• W2901938171 creator A5027721364 @default.
• W2901938171 creator A5032290025 @default.
• W2901938171 creator A5036988600 @default.
• W2901938171 creator A5037966102 @default.
• W2901938171 creator A5044848093 @default.
• W2901938171 creator A5045311601 @default.
• W2901938171 creator A5045698950 @default.
• W2901938171 creator A5066308745 @default.
• W2901938171 creator A5069697353 @default.
• W2901938171 creator A5075117420 @default.
• W2901938171 creator A5076787033 @default.
• W2901938171 creator A5080533920 @default.
• W2901938171 creator A5082606841 @default.
• W2901938171 creator A5083385263 @default.
• W2901938171 creator A5085810268 @default.
• W2901938171 date "2018-11-29" @default.
• W2901938171 modified "2023-10-16" @default.
• W2901938171 title "External Validation and Revision of Thrombosis Lymphoma /Throly/ Score" @default.
• W2901938171 doi "https://doi.org/10.1182/blood-2018-99-115568" @default.
• W2901938171 hasPublicationYear "2018" @default.
• W2901938171 type Work @default.
• W2901938171 sameAs 2901938171 @default.
• W2901938171 citedByCount "2" @default.
• W2901938171 countsByYear W29019381712020 @default.
• W2901938171 crossrefType "journal-article" @default.
• W2901938171 hasAuthorship W2901938171A5003886811 @default.
• W2901938171 hasAuthorship W2901938171A5004490449 @default.
• W2901938171 hasAuthorship W2901938171A5007859032 @default.
• W2901938171 hasAuthorship W2901938171A5024688180 @default.
• W2901938171 hasAuthorship W2901938171A5027721364 @default.
• W2901938171 hasAuthorship W2901938171A5032290025 @default.
• W2901938171 hasAuthorship W2901938171A5036988600 @default.
• W2901938171 hasAuthorship W2901938171A5037966102 @default.
• W2901938171 hasAuthorship W2901938171A5044848093 @default.
• W2901938171 hasAuthorship W2901938171A5045311601 @default.
• W2901938171 hasAuthorship W2901938171A5045698950 @default.
• W2901938171 hasAuthorship W2901938171A5066308745 @default.
• W2901938171 hasAuthorship W2901938171A5069697353 @default.
• W2901938171 hasAuthorship W2901938171A5075117420 @default.
• W2901938171 hasAuthorship W2901938171A5076787033 @default.
• W2901938171 hasAuthorship W2901938171A5080533920 @default.
• W2901938171 hasAuthorship W2901938171A5082606841 @default.
• W2901938171 hasAuthorship W2901938171A5083385263 @default.
• W2901938171 hasAuthorship W2901938171A5085810268 @default.
• W2901938171 hasBestOaLocation W29019381711 @default.
• W2901938171 hasConcept C126322002 @default.
• W2901938171 hasConcept C143998085 @default.
• W2901938171 hasConcept C2777938653 @default.
• W2901938171 hasConcept C2778461978 @default.
• W2901938171 hasConcept C2779338263 @default.
• W2901938171 hasConcept C2780011451 @default.
• W2901938171 hasConcept C2780868729 @default.
• W2901938171 hasConcept C2908647359 @default.
• W2901938171 hasConcept C71924100 @default.
• W2901938171 hasConcept C72563966 @default.
• W2901938171 hasConcept C99454951 @default.
• W2901938171 hasConceptScore W2901938171C126322002 @default.
• W2901938171 hasConceptScore W2901938171C143998085 @default.
• W2901938171 hasConceptScore W2901938171C2777938653 @default.
• W2901938171 hasConceptScore W2901938171C2778461978 @default.
• W2901938171 hasConceptScore W2901938171C2779338263 @default.
• W2901938171 hasConceptScore W2901938171C2780011451 @default.
• W2901938171 hasConceptScore W2901938171C2780868729 @default.
• W2901938171 hasConceptScore W2901938171C2908647359 @default.
• W2901938171 hasConceptScore W2901938171C71924100 @default.
• W2901938171 hasConceptScore W2901938171C72563966 @default.
• W2901938171 hasConceptScore W2901938171C99454951 @default.
• W2901938171 hasIssue "Supplement 1" @default.
• W2901938171 hasLocation W29019381711 @default.
• W2901938171 hasOpenAccess W2901938171 @default.
• W2901938171 hasPrimaryLocation W29019381711 @default.
• W2901938171 hasRelatedWork W1982201580 @default.
• W2901938171 hasRelatedWork W2154967465 @default.
• W2901938171 hasRelatedWork W2355588589 @default.
• W2901938171 hasRelatedWork W2365903619 @default.
• W2901938171 hasRelatedWork W2371372815 @default.
• W2901938171 hasRelatedWork W2379497856 @default.
• W2901938171 hasRelatedWork W2395675806 @default.
• W2901938171 hasRelatedWork W2552243206 @default.
• W2901938171 hasRelatedWork W2792292372 @default.
• W2901938171 hasRelatedWork W2801779377 @default.
• W2901938171 hasVolume "132" @default.
• W2901938171 isParatext "false" @default.
• W2901938171 isRetracted "false" @default.
• W2901938171 magId "2901938171" @default.
• W2901938171 workType "article" @default.